Estimating Heterogeneous Treatment Effects in Asymptomatic Alzheimer’s Disease.

Alzheimer’s disease (AD) is a neurodegenerative disorder that progressively impairs memory and cognitive functions. Detecting and intervening in the asymptomatic stages of Alzheimer’s is crucial for slowing or preventing the onset of clinical symptoms. However, responses to preventive treatments often vary between individuals due to genetic heterogeneity. Understanding this variability can lead to more effective treatment strategies that are tailored to an individual's genetic profile.

This project aims to estimate and make inferences about heterogeneous treatment effects (HTEs) in asymptomatic AD based on genetic information. Specifically, we will explore how genetic variations influence an individual's response to early interventions aimed at preventing the progression to symptomatic Alzheimer's. By leveraging machine learning algorithms and comprehensive genomic information in the A4 cohort, this project seeks to develop methods that can identify subgroups of individuals who are more or less likely to benefit from anti-amyloid treatments.

The findings will provide critical insights into the genetic basis of treatment response variability in AD, paving the way for more personalized interventions in the early stages of the disease. This work aligns with the growing focus on precision medicine and has the potential to improve outcomes by offering more tailored therapeutic approaches for individuals at risk of developing Alzheimer's.

Alzheimer’s disease (AD) is a neurological disorder that gradually worsens over time, leading to memory loss and cognitive decline. Detecting and treating Alzheimer’s before symptoms appear is crucial to slowing down or preventing its progression. However, not everyone responds to early treatments in the same way, and much of this difference may be linked to genetics. This project is focused on understanding how a person’s genetic makeup can influence their response to treatments aimed at preventing Alzheimer’s. Specifically, we are studying how genetic differences affect the success of preventive treatments. By using advanced data analysis techniques and studying large genetic databases, we aim to identify which groups of people are more likely to benefit from early interventions. The goal of this research is to provide new insights into how genes affect treatment outcomes, allowing doctors to offer more personalized, effective treatments to individuals at risk of developing Alzheimer’s disease.